HomeAI · summaries
Storia in 2 fonti
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval in muscle-invasive bladder cancer patients who are eligible to receive cisplatin-based chemotherapy, AstraZeneca on Thursday reported positive phase 3 results for its Imfinzi, used alongside Padcev, in those who were cisplatin-ineligible.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
pharmaceutical-technology.com
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS - Pharmaceutical Technology
AstraZeneca’s targeted treatment helps patients live longer, along with preventing cancer recurrence.
- ·
fiercepharma.com
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval in muscle-invasive bladder cancer patients who are…